N/A N=231 A Comparative Study of an Innovative 3-lead Wireless Water Resistant Holter System and a Conventional Holter System
Cardiac Arrhythmia
Primary: Detection of Cardiac Arrhythmias — 107; 104 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Timing of Suture Removal to Reduce Scarring in Skin Surgery
Suture Related Complication
Primary: The Measured Difference in POSAS and VAS Scores Between 7-day and 10-day Groups — 12.9; 16.1; 19.5; 20.3 score on a scale
Phase 2 N=59 Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms
Depressive Disorder, Major
Primary: Percentage Change of the BOLD Signal — -0.08; 0.43 percentage change in BOLD signal
Phase 1 N=9 FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Acute Myeloid Leukemia · Myeloid Leukemia · Monocytic Leukemia
Primary: Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events — 0; 0; 0; 0 Count of Participants
Phase 3 N=118 Perioperative Pregabalin in Ureteroscopy
Kidney Stone · Pain, Postoperative · Addiction
Primary: Visual Analog Scale of Pain Score — 3.7; 2.0 units on a scale
N/A N=195 The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
Cancer · Quality of Life · Anxiety
Primary: Pediatric Quality of Life Cancer Module — 66.89; 68.41 score on a scale
N/A N=202 Parental Research on Interventions for Social Media
Underage Drinking
Primary: Acceptability (Parent)- Program Usefulness — 42 Participants
N/A N=330 Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19
COVID-19
Primary: Number of Subjects With Sustained Resolution of COVID-19 Signs and Symptoms Without Subsequent Symptom Recurrence or Disease Progression (Until the End of the Study)…
Phase 2 N=64 A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus
Cutaneous Lichen Planus
Primary: Percentage of Participants Achieving Investigator's Global Assessment-Treatment Success (IGA-TS) at Week 16 — 50.0; 21.9 percentage of participants — p=0.0129
Phase 2 N=51 HIPEC for Peritoneal Carcinomatosis
Peritoneal Carcinomatosis · Colorectal Cancer · Appendiceal Cancer
Primary: Completeness of Cytoreduction
Phase 2 N=164 DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway
Genetic Obesity
Primary: Stage 1: Number of Participants by Genotype Who Demonstrated a Significant Clinically Meaningful Response to Setmelanotide at the End of Stage 1 — 49; 0; 0; 2 Participants
N/A N=65 Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid
Type 2 Diabetes Mellitus
Primary: Changes in Liver Fat — 5.4; 7.3 percent liver fat — p=0.05
Phase 2 N=7 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube High Grade Serous Adenocarcinoma
Primary: Dose-limiting Toxicities (Phase I) — 2; 3 participants
N/A N=22 Impact of Meal Timing on Glycemic Profile in Latino Adolescents With Obesity
Pediatric Obesity · Meal Timing
Primary: Change in Insulinogenic Index From Baseline After Test Meal From Venous Sample — 268; 215; 153 Microunits per milliliter
Phase 3 N=86 A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Participants With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs — 85; 21 Participants